Proactive Investors - Run By Investors For Investors

ValiRx monitors working capital position amid talks to end subscription agreement with investor

ValiRX said it expects to announce the outcome of talks with European High Growth “shortly” and no longer intends to enter into further arrangements with the investor.
prostate cancer
The investment would have helped fund the Phase II trial of ValiRx's prostate cancer drug

ValiRx Plc (LON:VAL) said it is carefully monitoring its working capital position as advanced talks to terminate a subscription agreement with European High Growth Opportunities Securitisation Fund continue.

In late April, European High Growth agreed to subscribe for a total of 213mln shares in ValiRX at a price of 0.6p each, raising gross proceeds of £1.28mln.

READ: ValiRx secures cash to fund VAL201 trial through to completion

The money was to be drawn down in three equal tranches of £426,000, which would have helped fund the Phase II trial of ValiRx's prostate cancer drug, VAL201, through to completion.

However, last month ValiRX said it was in advanced discussions to terminate the agreement following a delay to the issue of Tranche 2 shares, and enter into a new convertible bond facility with the investor. 

READ: ValiRx in talks to terminate subscription agreement and enter into a new convertible bond facility

The biotechnology company on Monday said it expects to announce the outcome of talks with European High Growth “shortly” and no longer intends to enter into further arrangements with the investor.

ValiRx added that it understands that European High Growth no longer has a holding in the company.

The group’s working capital position is dependent on new funds being raised in the short term so it has arranged to dispose of its investment in an unlisted security for £140,000. The proceeds are expected to be received in the next week.

ValiRx is also due to receive a £400,000 payment form the HMRC in July for a research and development tax credit.

“The directors will continue to monitor the company's working capital position and will make further announcements as necessary,” it said.

View full VAL profile View Profile

ValiRx PLC Timeline

Big Picture
May 02 2019

Related Articles

rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use